Evidence map›Paper›PMID 24604591›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2014

Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.

Sarah M Cheal, Blesida Punzalan, Michael G Doran, Michael J Evans, Joseph R Osborne, Jason S Lewis, Pat Zanzonico, Steven M Larson

Registry-linked trialAbstract readComparative Study
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06750419 (A Confirmatory, Open-label, Single-arm, Multi-centre Study to Evaluate Safety, Tolerability and Diagnostic Performance of 89Zirconium-labelled Girentuximab), which is not on this map. Cited by 43 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06750419 phase3recruitingnot on this mapstarted 2024, after this paper: background citation

A Confirmatory, Open-label, Single-arm, Multi-centre Study to Evaluate Safety, Tolerability and Diagnostic Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) to Non-invasively Detect Clear Cell Renal Cell Carcinoma (ccRCC) by Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Chinese Patients With Indeterminate Renal Masses (ZIRCON-CP Study)

TypeinterventionalSponsorTelix Pharmaceuticals (Innovations) Pty LimitedRan2024 to 2026Enrolled82ConditionsClear Cell Renal Cell CarcinomaArms89Zr-TLX250 PET/CT
3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Carbonic Anhydrase Inhibitors in Oncology.Sub-cellular biochemistry · 2026
    Review
  6. Article
  7. EJNMMI research · 2025
    Article
  8. Article
  9. Review
  10. Preclinical evaluation and automated synthesis of [EJNMMI radiopharmacy and chemistry · 2024
    Article
  11. Article
  12. Advances and challenges in immunoPET methodology.Frontiers in nuclear medicine · 2024
    Review
  13. Article
  14. Article
  15. Molecular Imaging Diagnosis of Renal Cancer UsingDiagnostics (Basel, Switzerland) · 2023
    Review
  16. ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Sarah M ChealDepartment of Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Blesida Punzalan
Michael G Doran
Michael J Evans
Joseph R Osborne
Jason S Lewis
Pat Zanzonico
Steven M Larson
Memorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Yu Chen, MICHAEL J MORRIS · 2001 to 2026
$63.0M
Tumor Evolution and Changes in MetabolismP50CA086438 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI RIVIERI, ISABELLE · 2000 to 2015
$29.9M
Molecular Imaging: Training for OncologyR25CA096945 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI HRICAK, HEDVIG · 2002 to 2013
$5.2M
Memorial Sloan Kettering Small Animal Imaging ResearchR24CA083084 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI KOUTCHER, JASON ARTHUR · 1999 to 2006
$4.4M
Noninvasive measurement of oncogenic signaling pathways with 89Zr-transferrinR00CA172695 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI EVANS, MICHAEL JOHN · 2014 to 2016
$728k
Immuno-PET With Anti-PSMA 89Zr-J591 mAb For Molecular Imaging of Prostate CancerR21CA153177 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI OSBORNE, JOSEPH REGINALD · 2011 to 2012
$404k
NCI NIH HHS P30 CA008748NCI NIH HHS P30-CA08748NCI NIH HHS P50 CA086438NCI NIH HHS P50 CA 086438-13NCI NIH HHS P50 CA092629NCI NIH HHS P50-CA92629NCI NIH HHS R00 CA172695NCI NIH HHS R21 CA153177NCI NIH HHS R21 CA153177-03NCI NIH HHS R24 CA083084NCI NIH HHS R24-CA83084NCI NIH HHS R25 CA096945NCI NIH HHS R25-CA096945
6 · The paper itself

Abstract

purposeThe PET tracer, (124)I-cG250, directed against carbonic anhydrase IX (CAIX) shows promise for presurgical diagnosis of clear-cell renal cell carcinoma (ccRCC) (Divgi et al. in Lancet Oncol 8:304-310, 2007; Divgi et al. in J Clin Oncol 31:187-194, 2013). The radiometal (89)Zr, however, may offer advantages as a surrogate PET nuclide over (124)I in terms of greater tumor uptake and retention (Rice et al. in Semin Nucl Med 41:265-282, 2011). We have developed a nonlinear immunokinetic model to facilitate a quantitative comparison of absolute uptake and antibody turnover between (124)I-cG250 and (89)Zr-cG250 using a human ccRCC xenograft tumor model in mice. We believe that this unique model better relates quantitative imaging data to the salient biological features of tumor antibody-antigen binding and turnover.

methodsWe conducted experiments with (89)Zr-cG250 and (124)I-cG250 using a human ccRCC cell line (SK-RC-38) to characterize the binding affinity and internalization kinetics of the two tracers in vitro. Serial PET imaging was performed in mice bearing subcutaneous ccRCC tumors to simultaneously detect and quantify time-dependent tumor uptake in vivo. Using the known specific activities of the two tracers, the equilibrium rates of antibody internalization and turnover in the tumors were derived from the PET images using nonlinear compartmental modeling.

resultsThe two tracers demonstrated virtually identical tumor cell binding and internalization but showed markedly different retentions in vitro. Superior PET images were obtained using (89)Zr-cG250, owing to the more prolonged trapping of the radiolabel in the tumor and simultaneous washout from normal tissues. Estimates of cG250/CAIX complex turnover were 1.35 - 5.51 × 10(12) molecules per hour per gram of tumor (20 % of receptors internalized per hour), and the ratio of (124)I/(89)Zr atoms released per unit time by tumor was 17.5.

conclusionPairwise evaluation of (89)Zr-cG250 and (124)I-cG250 provided the basis for a nonlinear immunokinetic model which yielded quantitative information about the binding and internalization of radioantibody bound to CAIX on tumor cells in vivo. (89)Zr-cG250 is likely to provide high-quality PET images and may be a useful tool to quantify CAIX/cG250 receptor turnover and cG250-accessible antigen density noninvasively in humans.

Indexed as

Positron-Emission TomographyAnimalsAntibodies, MonoclonalAntigens, NeoplasmCarbonic Anhydrase IXCarbonic AnhydrasesCarcinoma, Renal CellCell Line, TumorHumansIodine RadioisotopesKineticsMiceProtein BindingTissue DistributionXenograft Model Antitumor AssaysZirconiumAntibodies, MonoclonalAntigens, NeoplasmCA9 protein, humanCarbonic Anhydrase IXCarbonic AnhydrasesG250 monoclonal antibodyIodine RadioisotopesZirconium

Identifiers

PMID24604591
PMCPMC4120276
OpenAlexW1987729908

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.